Literature DB >> 22215706

Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia.

Augustine Rajakumar1, Ana Sofia Cerdeira, Sarosh Rana, Zsuzsanna Zsengeller, Lia Edmunds, Arun Jeyabalan, Carl A Hubel, Isaac E Stillman, Samir M Parikh, S Ananth Karumanchi.   

Abstract

The cardinal manifestations of the pregnancy-specific disorder preeclampsia, new-onset hypertension, and proteinuria that resolve with placental delivery have been linked to an extracellular protein made by the placenta, soluble fms-like tyrosine kinase 1 (sFlt1), that injures the maternal vasculature. However, the mechanisms by which sFlt1, which is heavily matrix bound, gain access to the systemic circulation remain unclear. Here we report that the preeclamptic placenta's outermost layer, the syncytiotrophoblast, forms abundant "knots" that are enriched with sFlt1 protein. These syncytial knots easily detach from the syncytiotrophoblast, resulting in free, multinucleated aggregates (50-150 μm diameter) that are loaded with sFlt1 protein and mRNA, are metabolically active, and are capable of de novo gene transcription and translation. At least 25% of the measurable sFlt1 in the third-trimester maternal plasma is bound to circulating placental microparticles. We conclude that detachment of syncytial knots from the placenta results in free, transcriptionally active syncytial aggregates that represent an autonomous source of sFlt1 delivery into the maternal circulation. The process of syncytial knot formation, shedding of syncytial aggregates, and appearance of placental microparticles in the maternal circulation appears to be greatly accelerated in preeclampsia and may contribute to the maternal vascular injury that characterizes this disorder.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22215706      PMCID: PMC3319764          DOI: 10.1161/HYPERTENSIONAHA.111.182170

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  43 in total

1.  Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer.

Authors:  C J Kuo; F Farnebo; E Y Yu; R Christofferson; R A Swearingen; R Carter; H A von Recum; J Yuan; J Kamihara; E Flynn; R D'Amato; J Folkman; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Placental debris, oxidative stress and pre-eclampsia.

Authors:  C W Redman; I L Sargent
Journal:  Placenta       Date:  2000-09       Impact factor: 3.481

3.  An in vitro model of human placental trophoblast deportation/shedding.

Authors:  M H Abumaree; P R Stone; L W Chamley
Journal:  Mol Hum Reprod       Date:  2006-09-20       Impact factor: 4.025

4.  Trophoblast deportation in human pregnancy--its relevance for pre-eclampsia.

Authors:  M Johansen; C W Redman; T Wilkins; I L Sargent
Journal:  Placenta       Date:  1999-09       Impact factor: 3.481

5.  Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women.

Authors:  A Rajakumar; H M Michael; P A Rajakumar; E Shibata; C A Hubel; S Ananth Karumanchi; R Thadhani; M Wolf; G Harger; N Markovic
Journal:  Placenta       Date:  2005-08       Impact factor: 3.481

6.  Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  2000-07       Impact factor: 8.661

7.  Phenotype and mRNA expression of syncytiotrophoblast microparticles isolated from human placenta.

Authors:  Belinda Kumpel; May-Jean King; Suren Sooranna; Dave Jackson; Jane Eastlake; Rong Cheng; Mark Johnson
Journal:  Ann N Y Acad Sci       Date:  2008-08       Impact factor: 5.691

8.  Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women.

Authors:  A Rajakumar; R W Powers; C A Hubel; E Shibata; F von Versen-Höynck; D Plymire; A Jeyabalan
Journal:  Placenta       Date:  2008-11-17       Impact factor: 3.481

Review 9.  Circulating microparticles in normal pregnancy and pre-eclampsia.

Authors:  C W G Redman; I L Sargent
Journal:  Placenta       Date:  2008-01-14       Impact factor: 3.481

Review 10.  Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.

Authors:  Camille E Powe; Richard J Levine; S Ananth Karumanchi
Journal:  Circulation       Date:  2011-06-21       Impact factor: 29.690

View more
  52 in total

Review 1.  Molecular Mechanisms of Preeclampsia.

Authors:  Tammy Hod; Ana Sofia Cerdeira; S Ananth Karumanchi
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-20       Impact factor: 6.915

2.  The anti-inflammatory effect of calcium for preventing endothelial cell activation in preeclampsia.

Authors:  J DeSousa; M Tong; J Wei; L Chamley; P Stone; Q Chen
Journal:  J Hum Hypertens       Date:  2015-07-09       Impact factor: 3.012

3.  Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia.

Authors:  Suzanne D Burke; Zsuzsanna K Zsengellér; Eliyahu V Khankin; Agnes S Lo; Augustine Rajakumar; Jennifer J DuPont; Amy McCurley; Mary E Moss; Dongsheng Zhang; Christopher D Clark; Alice Wang; Ellen W Seely; Peter M Kang; Isaac E Stillman; Iris Z Jaffe; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

Review 4.  Placental extracellular vesicles and feto-maternal communication.

Authors:  M Tong; L W Chamley
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

Review 5.  Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis.

Authors:  Kathryn J Gray; Richa Saxena; S Ananth Karumanchi
Journal:  Am J Obstet Gynecol       Date:  2017-11-11       Impact factor: 8.661

Review 6.  Low molecular weight heparin for the prevention of severe preeclampsia: where next?

Authors:  Kelsey McLaughlin; Ralph R Scholten; John D Parker; Enrico Ferrazzi; John C P Kingdom
Journal:  Br J Clin Pharmacol       Date:  2018-01-29       Impact factor: 4.335

7.  AP39, a Modulator of Mitochondrial Bioenergetics, Reduces Antiangiogenic Response and Oxidative Stress in Hypoxia-Exposed Trophoblasts: Relevance for Preeclampsia Pathogenesis.

Authors:  Ambart E Covarrubias; Edouard Lecarpentier; Agnes Lo; Saira Salahuddin; Kathryn J Gray; S Ananth Karumanchi; Zsuzsanna K Zsengellér
Journal:  Am J Pathol       Date:  2018-10-11       Impact factor: 4.307

8.  Placental growth factor: as an early second trimester predictive marker for preeclampsia in normal and high-risk pregnancies in a Turkish population.

Authors:  Necmiye Dover; Hacer C Gulerman; Sevki Celen; Serkan Kahyaoglu; Okan Yenicesu
Journal:  J Obstet Gynaecol India       Date:  2012-11-02

Review 9.  Morphological changes of placental syncytium and their implications for the pathogenesis of preeclampsia.

Authors:  Cynthia S Roland; Jian Hu; Chun-E Ren; Haibin Chen; Jinping Li; Megan S Varvoutis; Lynn W Leaphart; David B Byck; Xueqiong Zhu; Shi-Wen Jiang
Journal:  Cell Mol Life Sci       Date:  2015-10-26       Impact factor: 9.261

10.  Vascular pool of releasable soluble VEGF receptor-1 (sFLT1) in women with previous preeclampsia and uncomplicated pregnancy.

Authors:  Tracey L Weissgerber; Augustine Rajakumar; Ashley C Myerski; Lia R Edmunds; Robert W Powers; James M Roberts; Robin E Gandley; Carl A Hubel
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.